Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The biotech's share price soared as it developed its coronavirus vaccine candidate. The next catalyst will be revenue.

Moderna Stock: Buy at the High?

Here's What Could Make Moderna's COVID Vaccine a Bigger Winner Than Pfizer's

AstraZeneca

Biogen

BioNTech SE

GlaxoSmithKline

Pfizer

Sanofi

Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021. The post The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure appeared first on InvestorPlace.

The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure

The country's healthcare regulator is currently reviewing mRNA-1273 for approval.

Switzerland Increases Its Order for Moderna's Coronavirus Vaccine by Two-Thirds

Shares of Moderna gained as much as 7% on Tuesday to reach $170. The jump came as Morgan Stanley said that the drugmaker may provide the vast majority of vaccine doses to the US and make up for a potential shortfall of Pfizer vaccines. The US reportedly rejected an offer from Pfizer for more COVID-19 vaccine doses, and may only be able to order 100 million Pfizer doses until at least next June. According to Morgan Stanley, Moderna will deliver 20 million doses of its vaccine to the US before the end of 2020, and an additional 85 million to 100 million doses in the first quarter of 2021.

Moderna climbs 7% as Morgan Stanley says it could fill a vaccine-demand void left by Pfizer (MRNA)

Moderna (MRNA) announces deal to supply 20 million additional doses of its COVID-19 vaccine candidate, mRNA-1273, to the Canadian Government, upon potential approval. The total tally is now 40 million doses.

Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to Canada

Teladoc

10X Genomics

Veeva Systems

Here's how these big businesses became enormous during a year most of us would rather forget.

These 5 Large-Cap Healthcare Stocks Had the Best Gains in 2020

Novavax

Are the big gains over? No. But the game is changing.

How to Buy Coronavirus Vaccine Stocks in 2021

Moderna Inc. said Tuesday the Swiss government has increased its order for Moderna's COVID-19 vaccine candidate to 7.5 million doses from an original 4.5 million. Moderna said it's on track to start delivering the vaccine as soon as it gets the nod from Swiss regulators.

Moderna says Swiss government has increased its COVID vaccine order to 7.5 million doses from 4.5 million

The latest IBD/TIPP Poll shows just 52% of Americans are likely to get a coronavirus vaccine — a fact that could hamstring Pfizer and Moderna, the makers of the two front-running drugs. The post Pfizer, Moderna Face Public-Relations Hurdle For Covid Vaccines: IBD/TIPP Poll appeared first on Investor's Business Daily.

Pfizer, Moderna Face Public-Relations Hurdle For Covid Vaccines: IBD/TIPP Poll

Experts maintain that widespread rollout of these vaccines, which have undergone rigorous testing, is very likely to be safe.

No, the Pfizer and Moderna vaccine development has not been ‘reckless.'

The companies with the biggest gains won't necessarily be those with the highest sales of coronavirus vaccines.

$40 Billion COVID Vaccine Market in 2021: These 3 Stocks Are Likely to Be the Biggest Winners

The company says it can start delivering the vaccine as soon as this month.

Canada Doubles Its Commitment to Moderna's Coronavirus Vaccine to 40 Million Doses

The two companies will be conspicuous by their absence at an event some administration sources are viewing as a publicity stunt for President Donald Trump.

Pfizer And Moderna Steer Clear Of White House Vaccine Summit

Shares of Moderna Inc. rallied 1.3% in morning trading Monday, after the biotechnology company said the Canadian government has doubled its order commitment for the company's COVID-19 vaccine candidate. Canada has exercised its option to order an additional 20 million doses of the vaccine candidate, bringing the confirmed order commitment to 40 million doses.

Moderna's stock rallies after Canada doubles order for COVID-19 vaccine candidate

The stock price of Moderna Inc (NASDAQ: MRNA) has received a price target increase from $105 to $150 by Bank of America recently. These are the details.

Moderna Stock Price: $150 Target By Bank Of America

The biotech announced a string of great news about its coronavirus vaccine candidate.

Why Moderna Stock Skyrocketed 126% in November

Exxon Mobil

Here are the top stocks to choose from in our new bull market.

The 3 Best Stocks to Buy Right Now

Nasdaq

Moderna, Inc. (MRNA) CEO Stéphane Bancel Presents at NASDAQ 43rd Virtual Investor Conference (Transcript)

Moderna Inc will be able to produce 500 million doses of its COVID-19 vaccine in 2021, Chief Executive Officer Stéphane Bancel said on Friday.

Moderna CEO confident of producing 500 million COVID-19 vaccine doses in 2021

BioCryst Pharmaceuticals

Eli Lilly

Sutro Biopharma Inc

Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutro Biopharma is a clinical stage company developing and manufacturing therapeutics.

Why BioCryst, Moderna And More Are Moving Today

Moderna Inc. said Friday it is amending its supply agreement with the Israeli health ministry and will provide an additional 4 million doses of its experimental COVID-19 vaccine mRNA-1273. The amendment brings the total number of doses secured by Israel to 6 million.

Moderna to provide Israel health ministry with additional 4 million doses of its COVID-19 vaccine candidate

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces amendment to supply agreement with the Ministry of Health of Israel to supply additional doses of mRNA vaccine against COVID-19.

Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Shares of the risky biotech stock are at an all-time high.

Should You Sell Your Moderna Stock Now?

There's more ahead than just a regulatory green light.

News for Moderna Stock (MRNA)